The long noncoding RNAs (lncRNAs) have been increasingly appreciated as key players underlying tumourigenesis and hold great potentials as prognostic biomarkers and therapeutic targets. However, their roles in head neck squamous cell carcinoma (HNSCC) have remained incompletely known. Here, we sought to reveal the oncogenic roles and clinical significance of a tumour-associated lncRNA, zinc finger E-box binding homeobox 2 antisense RNA 1 (ZEB2-AS1), in HNSCC. ZEB2-AS1 was aberrantly overexpressed in a fraction of HNSCC samples. Its overexpression significantly associated with large tumour size, cervical node metastasis and reduced overall and disease-free survival. Antisense oligonucleotides (ASO)-mediated ZEB2-AS1 depletion markedly inhibited cell proliferation, migration and invasion while triggered apoptosis in HNSCC cells in part via modulating ZEB2 mRNA stability. Enforced overexpression of ZEB2 largely attenuated the phenotypic changes resulted from ZEB2-AS1 inhibition except the impaired cell proliferation. In addition, ZEB2-AS1 was required for TGF-β1-induced epithelial-mesenchymal transition (EMT) in vitro.
| INTRODUC TI ON
Head neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with about 500 000 new cases diagnosed each year and also remains as one leading cause of cancer-related death. 1 Although comprehensive treatment regime including surgical resection, radiotherapy and chemotherapy has been established for years, the overall 5-year survival rate of HNSCC patients has not been significantly improved over the past decades. 2 A large fraction of patients has been definitively diagnosed with diseases in advanced stages, thus precluding early and timely clinical management of these malignancies. Several prognostic factors like clinical stage, invasive depth, status of surgical margins as well as cervical node involvement have been identified to be significantly associated with local recurrence, distant metastasis and patient survival. 3 However, these prognostic biomarkers for HNSCC are still far from optimal. These unmet challenges in HNSCC diagnosis, treatment and prognostic prediction highlight the urgent need to identify optimal biomarkers and druggable targets.
The past decades have witnessed tremendous progress in genomic profiling and functional interrogation of noncoding RNAs in human cancer. Among these cancer-related noncoding RNA species, long noncoding RNAs (lncRNAs) are a class of transcripts longer than 200 nucleotides which have been increasingly appreciated as key players underlying tumourigenesis. 4 Accumulating evidence has suggested that aberrantly deregulated lncRNAs have linked to cancer initiation and overgrowth, metastatic spreading and therapeutic resistance. 4, 5 These lncRNAs usually modulate gene expression at the chromatin organization, transcriptional or posttranscriptional levels as decoys, guides or scaffolds. 6 Noticeably, natural antisense transcript (NAT), a specific class of lncRNA, is transcribed from the opposite DNA strand to other transcripts and overlaps in part with sense RNA, which has lineage-specific or cancer-specific expression manner. 7, 8 A number of molecular mechanisms including transcription-related modulation, RNA-DNA interaction and RNA-RNA interaction have been proposed for antisense-mediated regulation of cognate sense RNA. 9, 10 To date, genomic transcriptional profiling and function dissection of lncRNA in HNSCC remains far from complete. Several lncRNA such as HOTAIR, H19
and DLEU1 have been revealed to facilitate initiation and progression of HNSCC and their overexpression serve as diagnostic and prognostic biomarkers. [11] [12] [13] However, quite few NATs have been identified as key oncogene or tumour suppressor in HNSCC thus far. The lncRNA zinc finger E-box binding homeobox 2 antisense RNA1 (ZEB2-AS1) has attracted our attentions as it was highly expressed in several solid cancers like hepatocellular carcinoma, lung cancer and pancreatic cancer. Moreover, it usually promoted cell proliferation, invasion and EMT while inhibited apoptosis in diverse cancer contexts. [14] [15] [16] [17] These findings suggested that ZEB2-AS1 was an oncogenic NAT with incompletely delineated roles in human cancer. However, the expression and biological roles of ZEB2-AS1 underlying HNSCC remain largely unexplored yet.
In the present study, we sought to determine the expression pattern of ZEB2-AS1 in primary HNSCC and uncover its roles during HNSCC tumourigenesis by loss-of-function assay and xenograft animal model.
| MATERIAL S AND ME THODS

| Patients and tissue specimens
A total of 71 pairs of fresh HNSCC and adjacent non-tumour mucosa were included from patients treated in Department of Oral and Maxillofacial Surgery, Affiliated Stomatological Hospital, Nanjing
Medical University from January 2011 to December 2017. All patients were diagnosed as primary HNSCC without any prior treatments and underwent radical resection at our institution. All tissue samples were snap-frozen in liquid nitrogen and stored in at −80°C until RNA extraction. Written informed consent was obtained from these patients. Detailed information including epidemiologic, clinical, pathological and follow-up data for each patient was available.
This study protocol was reviewed and approved by the Research Ethics Committee of Nanjing Medical University. supplemented with 10% FBS (Gibco) and penicillin-streptomycin (1%), and maintained at 37°C in a 5% CO 2 -humidified incubator. For TGF-β1-induced EMT cellular model in vitro, cells were treated with recombinant human TGF-β1 (rhTGF-β1, 10 ng/mL, R&D Systems) for indicated time-points. Subsequently, changes of cell morphology and EMT-relevant markers were monitored accordingly.
| HNSCC cell lines and cell culture
| Antisense oligonucleotides (ASO) biosynthesis, small interfere RNAs, lentiviral construct and transfection
The antisense oligonucleotides specifically targeting human ZEB2-AS1 (Gene ID: 100303491) including ASO-ZEB2-AS1-92 (5'-A*C*A*C* T*T*C*G*C*G*G*C*T*T*C*T*T*C*A*T-3'), ASO-ZEB2-AS1-265 (5'-G* C*T*C*A*G*G*G*C*G*C*T*T*C*A*A*T*T*A*T-3') and ASO-ZEB2-AS1-316 (5'-A*T*G*C*C*C*T*A*A*G*A*T*G*C*A*G*C*T*C*C-3') (*indicative of phosphorothioate) were designed and purchased from Sangon Biotech (Shanghai, China). This phosphorothioate modification was aimed to enhance stability and efficiency of ASO both in vitro and in vivo. 18, 19 For ZEB2 knockdown, two independent small interference RNAs (siRNA) were designed and synthesized. To characterize the location of ZEB2-AS1 in HSNCC cells, cytoplasmic and nuclear fractions of FaDu and Cal27 cells were prepared and collected using the PARIS TM Kit (Life Technologies, Carlsbad, CA, USA). 18S rRNA was used as the endogenous cytoplasmic control.
U6 small nuclear RNA was used as the endogenous nuclear control.
The nuclear and cytoplasmic RNA was further analysed by qRT-PCR.
Relative mRNA or lncRNA expression was quantified as compared to internal control GAPDH or U6 using comparative CT method.
| CCK-8, colony formation and cell apoptosis assay
Cell proliferation and viability were assessed by absorbance using CCK-8 cell viability assay (Cell Counting Kit-8, Dojindo, Japan).
Control and ASO-ZEB2-AS1-treated HNSCC cells were seeded into the 96-well plates at an initial density of 1 × 10 3 cells per well.
CCK-8 solution (10 μL/well) was added to the cells at specified timepoints. For colony formation assay, 1000 single cells pretreated with ASO-ZEB2-AS1 were seeded into 6-well plates and allowed to grow for 12 days. After stained with crystal violet, the colonies were visualized under microscope, photographed and counted. For cell apoptosis assay, cells were treated with trypsin (Gbico), resuspended as single-cell suspension and then stained with Annexin V:
PE Apoptosis Detection Kit (BD Bioscience).
| Cell migration and invasion assay
Cell migration and invasion assays in vitro were performed with wound healing and transwell chambers (8-μm pore size, Corning)
with Matrigel (BD Pharmingen) pre-coating as we previously reported.
20,21
| Western blot analysis
Cells in culture flasks or plates were lysed in ice-cold buffer con- 
| Cellular immunofluorescence assay
For immunofluorescence assays, cells were seeded on glass cover- 
| HNSCC xenograft model and tail vein injection lung metastasis mouse model
All experiments involving animal subjects were in accordance with the institutional animal welfare guidelines and approved by
Institutional Animal Care and Use Committee of Nanjing Medical
University.
Six-week-old female nu/nu mice were obtained and maintained 
| Statistical analysis
All quantitative data in the present study were shown as mean ± SD from two or three independent experiments and compared with expression when the median of ZEB2-AS1 expression was utilized as cut-off. As detailed in Table S1 , overexpression of ZEB2-AS1 was significantly associated with larger tumour size (P = 0.0287) and cervical node metastasis (P = 0.0321). We failed to identify the associations between ZEB2-AS1 and other demographic or clinicopathological parameters. Moreover, as shown in Figure 1C ,D, results from Kaplan-Meier analyses indicated that patients with higher ZEB2-AS1 expression had inferior overall survival (OS) and diseasefree survival (DFS) than those with lower ZEB2-AS1 expression (P = 0.0145, 0.0115, Log-rank test). More importantly, our univariate and multivariate Cox regression assays both revealed that status of ZEB2-AS1 expression was an independent prognostic factor for HNSCC survival (Table S2) , strongly suggesting its potential as a novel prognostic biomarker.
| ZEB2-AS1 knockdown inhibited cell proliferation and induced apoptosis in HNSCC cells
Next, we set out to determine the biological roles of ZEB2-AS1
in HNSCC by loss-of-function assay. We firstly measured the As shown in Figure S1 , although three ASO significantly reduced the ZEB-AS1 expression in both cells, the ASO-316 showed the highest potency and then was selected for following experiments.
This ASO-316 (hereafter named as ASO-ZEB2-AS1 for simplicity) robustly reduced endogenous ZEB2-AS1 in both Cal27 and FaDu cells ( Figure 2C ). Subsequently, we monitored the phenotypic changes upon ZEB2-AS1 depletion in vitro. Cell proliferation was significantly inhibited in both cells upon ZEB2-AS1 knockdown as demonstrated by the data from CCK-8 assay ( Figure 2D ) and colony formation assay ( Figure 2E ) as compared to the control. In addition, results derived from flow cytometric assay revealed that the proportions of apoptotic cells in ASO-ZEB2-AS1-treated cells were significantly increased from 2.8% to 11.0% in Cal27, from 5.6% to 22.9% in FaDu respectively ( Figure 2F ). In line with this, the expression of apoptosis marker Cleaved-PARP was markedly elevated in ASO-ZEB2-AS1-treated cells ( Figure 2G ).
| ZEB2-AS1 knockdown inhibited cell proliferation, migration and invasion in HNSCC cells by stabilizing ZEB2 mRNA
Next, we performed wound healing and transwell invasion assays to measure cell migratory and invasive potentials of Cal27 and FaDu following ZEB2-AS1 depletion. As shown in Figure 3A -C, both migratory and invasive properties of cells were significantly impaired after ZEB2-AS1 knockdown in HNSCC cells. The levels of EMT-related markers were further measured by western blot. As shown in Figure 3D , up-regulation of E-cadherin and down-regulation of Ncadherin, Vimentin and Snail were detected upon ZEB2-AS1 knockdown, which suggested inhibition of EMT following ASO-ZEB2-AS1 introduction in HNSCC cells.
Considering the pro-invasive roles of ZEB2-AS1 in HNSCC cells and the well-defined roles of ZEB2 in EMT and cancer invasion, 22, 23 we speculated that ZEB2-AS1 might exert its function by regulating ZEB2. To address this, we firstly performed ZEB2 knockdown assay and monitored the resulting phenotypic changes in vitro. As displayed in Figure S2 , siRNA-mediated ZEB2 knockdown significantly inhibited cell proliferation, migration and invasion in vitro, which largely phenocopied ZEB2-AS1 inhibition induced by ASOs in HNSCC cells. Thus, these findings suggested that ZEB2-AS1 might promote HNSCC progression by regulating ZEB2 expression. Indeed, some previous reports have offered vital clues regarding ZEB2-AS1 in modulating ZEB2 expression in diverse contexts. 24, 25 As shown in Figure 4A Figure S4D ,E). In addition, data mining and interrogation of TCGA-HNSCC data set had revealed significant correlation between ZEB2-AS1 and ZEB2 mRNA in HNSCC ( Figure   S4F ). Collectively, these data support that ZEB2-AS1 functions by promoting ZEB2 abundance via stabilizing its mRNA in HNSCC cells.
| ZEB2-AS1 is involved in TGF-β1-induced EMT in HNSCC
Mounting evidence indicates that EMT-mediated metastatic spread dictates patients survival in various solid cancers including HNSCC. 23 Our in vitro loss-of-function assays suggested the potential roles of ZEB2-AS1 involving EMT and invasion of HNSCC. Thus, we next aimed to determine whether ZEB2-AS1 has the EMT-inducing role in HNSCC via the conical TGF-β1-inducing EMT model. 20, 26 Both ZEB2-AS1 and ZEB2 were significantly up-regulated when cells were incubated with rhTGF-β1 for 48 hours. However, when cells were treated with ASO-ZEB2-AS1, rhTGF-β1 alone or in combination, up-regulation of ZEB2-AS1 and ZEB2 mRNA after rhTGF-β1 exposure was largely abrogated when ASO-ZEB2-AS1 was added simultaneously ( Figure 6A,B) . Consistently, as expected, our western blot and immunofluorescence assays indicated that rhTGF-β1 treatment resulted in ZEB2, N-cadherin and Vimentin up-regulation and E-cadherin down-regulation, whereas ZEB2-AS1 knockdown largely abolished these effects of rhTGF-β1 ( Figure 6C ; Figure S5 ).
Moreover, in line with these marker changes, TGF-β1-induced enhancement of cell migration was significantly impaired following ZEB2-AS1 knockdown ( Figure 6D ). and ZEB2-AS1-ASO was inoculated, the tumours generated from ZEB2-AS1-ASO-treated cells were much smaller with much less volume and weight as compared to negative control ( Figure 7A-C) .
However, we failed to identify the difference of tumour incidence between two types of grafts, although the delay of tumour onset in grafts of ZEB2-AS1-ASO-treated cells was observed (data not shown). Moreover, reduced Ki67 and ZEB2 immunostaining was observed in samples derived from ASO-ZEB2-AS1-transduced cells ( Figure 7D ). Next, we developed a systemic lung metastasis model by tail vein injection in nude mice to verify the pro-metastatic role of ZEB2-AS1 in vivo. As shown in Figure 7E , much fewer lung metastatic nodules were identified in ASO-ZEB2-AS1-treated cell injection as compared to control cells. Together, ZEB2-AS1 is critically involved in tumour overgrowth and metastasis of HNSCC.
| D ISCUSS I ON
The dismal prognosis of HNSCC highlights the critical need to identify more effective biomarker and druggable therapeutic targets with translational potentials. 2 Cancerous lncRNA stands out as an optimal candidate for cancer screen, patient stratification and prognostic prediction. 4, 5 Importantly, several oncogenic lncRNAs have been demonstrated with potent anti-cancer effects when they were therapeutically inhibited in vivo. 4, 27 Here, our results reveal that lncRNA ZEB2-AS1 probably serves as pro-oncogenic noncoding RNA by stabilizing ZEB2 mRNA and hold potentials as a novel prognostic biomarker and therapeutic target in HNSCC with its aberrant overexpression.
| Clinical significance of ZEB2-AS1 overexpression in HNSCC
Previous reports have delineated that ZEB2-AS1 is aberrantly upregulated in several types of human cancer and associated with tumour aggressiveness and unfavourable prognosis. 
| Tumourigenic roles of ZEB2-AS1 in HNSCC
Accumulating evidence has shown that ZEB2-AS1 primarily functioned as an oncogenic lncRNA in human cancer by promoting proliferation, invasion and MET and inhibiting apoptosis. [14] [15] [16] [17] In lung cancer cells, knockdown of ZEB2-AS1 inhibited cell proliferation and induced apoptosis by altering expression of Bcl-2, Bax and caspase3/9. 16 In addition, the effects on cell proliferation and apoptosis of ZEB2-AS1 were probably mediated by miR-27 in bladder cancer cell. 14 Moreover, ZEB2-AS1 exerted as a molecular sponge of miR-204 and in turn derepressed miR-204 target HMGB1 to facilitate pancreatic cancer growth and invasion both in vitro and in vivo. 15 Generally, consistent with these abovementioned findings, 
| Mechanisms responsible for ZEB2-AS1 in HNSCC tumourigenesis
Although the precise molecular mechanisms underlying ZEB2-AS1 during tumourigenesis remain incompletely known, previous studies have indicated that ZEB2-AS1 serves as molecular sponge for specific miRNA and subsequently derepresses the target of miRNA, which facilitates cancer overgrowth and dissemination. 14, 15 For example, miR-27 and miR-204 abundance was attenuated by ZEB2-AS1 overexpression and then increased targets of these miRNAs to modulate cancer aggressiveness in bladder and pancreatic cancer. 14, 15 Considering the facts that ZEB2-AS1 was a NAT corresponding to the 5′ UTR of ZEB2 and NAT might increase the stability of their target sense mRNAs by forming RNA duplex and masking specific sites that would otherwise resulted in mRNA degradation, 29, 30 we determined the stability of ZEB2 mRNA fol- In conclusion, our data reveal that ZEB2-AS1 is highly expressed in a fraction of HNSCC and its overexpression significantly associates 
